Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000234359 | SCV000291300 | benign | Multiple endocrine neoplasia, type 1 | 2025-01-23 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000454942 | SCV000539616 | uncertain significance | not specified | 2016-03-29 | criteria provided, single submitter | clinical testing | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Intronic 1bp del unlikely to impact splicing; ExAC: 0.1% (13/16474) South Asian chromosomes |
Ambry Genetics | RCV000566396 | SCV000673632 | likely benign | Hereditary cancer-predisposing syndrome | 2019-10-15 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Counsyl | RCV000234359 | SCV000786105 | likely benign | Multiple endocrine neoplasia, type 1 | 2018-03-01 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000566396 | SCV002530077 | benign | Hereditary cancer-predisposing syndrome | 2021-12-07 | criteria provided, single submitter | curation | |
Myriad Genetics, |
RCV000234359 | SCV004018043 | likely benign | Multiple endocrine neoplasia, type 1 | 2024-08-26 | criteria provided, single submitter | clinical testing | This variant is considered likely benign. This variant is intronic and is not expected to impact mRNA splicing. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. |
ARUP Laboratories, |
RCV003736666 | SCV004563448 | likely benign | not provided | 2023-11-14 | criteria provided, single submitter | clinical testing |